Home

Search Abstracts

Browse Sessions

Program Committee

Conference Webcasts

Contact Us

---

Session 77   Poster Abstracts New Antiretroviral Agents: RTI's and PI's Wednesday, 1:30 - 3:30 pm Poster Hall

526	Analysis of the Genotypes of Viruses Isolated from Patients after 10 Days Monotherapy with SPD754 P Collins*1, L Shiveley2, C Anderson2, and R Bethell1 1Shire Biochem, Laval, Canada and 2Shire Pharm. Inc., Rockville, MD, USA
527	Safety Profile of SPD754 in Cynomolgus Monkeys Treated for 52 Weeks C Locas*1, S Ching2, and S Damment3 1Shire Biochem, Laval, Canada; 2SVC Associates Inc., Laval, Canada; and 3Shire Pharm. Devt., Basingstoke, UK
528	Diarylpyrimidines and Diaryltriazines Constitute a New Class of Highly Active Non-Nucleoside Reverse Transcriptase Inhibitors Y Van Herrewege*1, J Michiels1, Z Kara1, K Andries2, M P de Béthune2, L Kestens1, P J Lewi3, P A J Janssen3, and G Vanham1 1Inst. of Tropical Med., Antwerp, Belgium; 2Tibotec, Mechelen, Belgium; and 3Janssen Pharmaceutica, Vosselaar, Belgium
529	Kinetic and Thermodynamic Parameters for Binding of the Non-nucleoside Inhibitors GW678248 and GW695634 to Wild Type and 12 Mutants of HIV-1 Reverse Transcriptase G Roberts*, D Porter, L Boone, J Chan, L Martin-Carpenter, P Gerondelis, S Short, and K Weaver GlaxoSmithKline, Research Triangle Park, NC, USA
530	Characterization of a Novel Series of Nevirapine-like Next-Generation NNRTI with Broad Antiviral Potency Against NNRTI-resistant HIV P R Bonneau*1, L Doyon1, J Duan1, B Simoneau1, C Yoakim1, R Déziel2, W Ogilvie3, L Bourgon1, M Garneau1, F Liard1, C Plouffe1, S Tremblay1, E Wardrop1, M Bös1, and M G Cordingley1 1Boehringer Ingelheim (Canada) Ltd., Res. and Devt., Laval, Canada; 2Methylgene, Montréal, Québec Canada; and 3Univ. of Ottawa, Ontario, Canada
531	Novel Tricyclic Non-Nucleoside Reverse Transcriptase Inhibitors with Improved Resistance Profiles B Johnson1, C Tarby1, A Srivastava1, R Bakthavatchalam2, L Bacheler2, S Diamond1, S Jeffrey2, R Klabe2, B Cordova2, S Garber2, K Logue2, S Erickson-Viitanen2, G Trainor*1, and J Rodgers1 1Bristol-Myers Squibb Co., Princeton, NJ, USA and 2DuPont Pharm. Co.,, Wilmington, DE, USA
532	SN1212/1461 a Novel Mutagenic Deoxyribonucleoside Analog with Activity against HIV K Harris*, B Brabant, L Li, S Styrchak, A Gall, and R Daifuku Koronis Pharm., Redmond, WA, USA
533	TMC114/RTV Activity in Multiple PI-experienced Patients: Correlation of Baseline Genotype, Phenotype, Pharmacokinetics, and IQ with Antiviral Activity at Day 14 M Peeters1, B Van Baelen1, S De Meyer1, M-P de Bethune1, H Muller1, R Hoetelmans1, E Lefebvre2, and E Delaporte* 1Tibotec, Mechelen, Belgium; 2Tibotec Inc., Yardley, PA, USA; and 3UR36, Inst of Res. and Devt., Montpellier, France